
(A)
FAS
P=0.42
Overall survival (%)
100
50
0
0
20
40
60
80
Time (months)
No. at risk
31 22 6 2 1
23 17 3 1 0
(B)
Group A
P=0.02
Overall survival (%)
100
50
0
0
20
40
60
Time (months)
No. at risk
6 6 4 1
6 6 1 0
Anlotinib and Apatinib
Bevacizumab
(C)
Group B
P=0.66
Overall survival (%)
100
50
0
0
20
40
60
80
Time (months)
No. at risk
20 15 3 2 1
10 8 3 1 0
(D)
Group C
P=0.95
Overall survival (%)
100
50
0
0
10
20
30
40
Time (months)
No. at risk
5 4 3 3 1
7 5 5 2 1
Anlotinib and Apatinib
Bevacizumab